Transcatheter Aortic Valve Replacement (TAVR) Market Overview
Transcatheter aortic valve replacement (TAVR) is described as a minimally invasive procedure replaces the improper functioning aortic valves. TAVR offers an efficient valve replacement procedure as compared to open-heart surgery for the benefit of high-risk patients. Transcatheter heart valve replacement systems are referred to as cardiovascular devices replace the old and damaged valves. TAVR is used for the treatment of aortic valve disorders such as severe aortic stenosis, degeneration, & regurgitation. Transcatheter aortic valve replacement devices are integrated with valve frame (made of nitinol or stainless steel), valve leaflets material (made of bovine or cow heart tissue). These aortic valves are available with varied sizes (such as 14mm, 16mm, 18mm, 20mm, 22mm, & 29mm). TAVR is performed during different surgery methods such as transfemoral implantation (through the femoral artery), transapical implantation (through the apex of the heart), transaortic implantation (through the top of right chest), and transcaval implantation (through the femoral vein).
Growing adoption of minimally invasive therapies, increasing number of severe aortic stenosis disorder patients, rising number of clinical trials cardiovascular indications, and growing number of product launches in this market are driving the growth of global transcatheter aortic valve replacement (TAVR) market. In addition, rising technological advancements, increasing demand for minimally invasive catheter-based procedures as compared to conventional open heart therapies, and growing number of patients choosing an efficient & effective therapy with quick recovery are further propelling the growth of global transcatheter aortic valve replacement (TAVR) market. However, risk associated with TAVR procedures, high costs pertaining to transcatheter aortic valves, lack of skilled professionals in certain regions of developing markets, and device related issues (such as device recalls, improper positioning of devices during implantation) are some of the factors restraining the growth of global transcatheter aortic valve replacement (TAVR) market.
Transcatheter Aortic Valve Replacement Market (TAVR) Market Insights
Transcatheter Aortic Valve Replacement (Tavr) Market Forecast Report (2018-2023)
Global Transcatheter Aortic Valve Replacement (Tavr) Market is expected to reach USD 6.03 billion by 2023 from USD 2.58 billion in 2018, growing at a CAGR of 18.50% during the forecast period 2018-2023.
Transcatheter Aortic Valve Replacement Market (TAVR) Market Segmentation
Global transcatheter aortic valve replacement (TAVR) market is segmented based on surgery method, valve frame material, valve size, valve leaflets material, and end users. Based on surgery method, the market is sub-segmented as transfemoral implantation, transapical implantation, transaortic implantation, and transcaval implantation. Of these, transfemoral is estimated to command the largest share of global transcatheter aortic valve replacement (TAVR) market by surgery method in 2018 and expected to grow at the highest CAGR during the forecast period. Based on valve frame material, the market is segmented as nitinol, stainless steel, and cobalt-chromium. Of these, nitinol segment is expected to account for the largest share of global transcatheter aortic valve replacement (TAVR) market by valve frame material in 2018.
Transcatheter valve size market is segmented as 14mm to 18mm, 18mm to 22mm, and 22mm to 29mm. Based on valve leaflets material, the market is segmented as bovine heart tissue, cow heart tissue, and other valve leaflets material. Based on end users, the market is sub-segmented as hospitals, ambulatory surgical centres, & cardiac catheterization laboratories. Of these, hospital segment held the largest share of global transcatheter aortic valve replacement (TAVR) market by end users in 2018.
On the basis of geographical region the global transcatheter aortic valve replacement (TAVR) market is segmented as North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. North America is estimated to command the highest share of 34% of the global transcatheter aortic valve replacement (TAVR) market in 2018, whereas Asia-Pacific is estimated to grow at the highest CAGR of 21.20% during the forecast period 2018-2023.
Key Players:
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Introduction
5.2 Surgery Method
5.2.1 Introduction
5.2.2 Transfemoral Implantation
5.2.3 Transapical Implantation
5.2.4 Transaortic Implantation
5.2.5 Transcaval Implantation
5.3 Valve Frame Material
5.3.1 Introduction
5.3.2 Nitinol
5.3.3 Stainless Steel
5.3.4 Cobalt-Chromium
5.4 Valve Size
5.4.1 Introduction
5.4.2 14mm to 18 mm
5.4.3 18mm to 22 mm
5.4.4 22mm to 29mm
5.5 Valve Leaflets Material
5.5.1 Introduction
5.5.2 Bovine Heart Tissue
5.5.3 Cow Heart Tissue
5.5.4 Other Valve Leaflets Material
5.6 End Users
5.6.1 Introduction
5.6.2 Hospitals
5.6.3 Ambulatory Surgical Centres
5.6.4 Cardiac Catheterization Laboratories
6. Geographical Analysis
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 Soth Korea
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle East
6.5.3 South Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Edwards Lifesciences Corporation (U.S.)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Medtronic, Inc. (Ireland)
8.3 Boston Scientific Corporation (U.S.)
8.4 Abbott Laboratories (U.S.)
8.5 St. Jude Medical Inc. (U.S.)
8.6 JenaValve Technology, Inc. (Germany)
8.7 Symetis SA (Switzerland)
8.8 Direct Flow Medical, Inc. (U.S.)
8.9 Sorin Group (Italy)
8.10 Meril Life Sciences India Pvt Ltd (India)
8.11 Braile Biomedica (Brazil)
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
